#1 Clinical Trials Search in Europe

Cevostamab

Cevostamab is an innovative drug being studied in clinical trials for the treatment of relapsed or refractory multiple myeloma (R/R MM). This article explores the ongoing research into cevostamab’s safety, effectiveness, and potential combinations with other therapies to improve outcomes for patients with this challenging form of blood cancer.

Table of Contents

What is Cevostamab?

Cevostamab, also known as BFCR4350A or RO7187797, is an investigational drug being developed for the treatment of multiple myeloma[1]. Multiple myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell responsible for producing antibodies. In multiple myeloma, these plasma cells become cancerous and multiply uncontrollably, leading to various health problems.

How Cevostamab Works

Cevostamab is a type of drug called a bispecific antibody. This means it can bind to two different targets at the same time. In the case of cevostamab, it targets a protein called FcRH5 on myeloma cells and CD3 on T cells (a type of immune cell). By bringing these cells together, cevostamab helps activate the T cells to attack and kill the myeloma cells[1].

Conditions Treated

Cevostamab is primarily being studied for the treatment of relapsed or refractory multiple myeloma (R/R MM). This refers to multiple myeloma that has either come back after previous treatment (relapsed) or has not responded well to standard treatments (refractory)[2]. Some specific patient groups being studied include:

  • Patients who have received at least three prior lines of therapy, including drugs like proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies[2]
  • Patients who have previously been treated with BCMA-targeted therapies (BCMA is another protein found on myeloma cells)[2]
  • Newly diagnosed patients with high-risk cytogenetic features (certain genetic changes that make the myeloma more aggressive) who have undergone stem cell transplantation[3]

How Cevostamab is Administered

Cevostamab is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. The dosing schedule can vary depending on the specific clinical trial, but generally involves:

  • A “step-up” dosing approach, where patients receive lower doses initially and then gradually increase to the full dose. This is done to help manage potential side effects[1].
  • Treatment cycles that last 21 or 28 days, with cevostamab given on specific days within each cycle[3].
  • Treatment may continue for a set number of cycles (e.g., up to 17 cycles) or until the disease progresses or unacceptable side effects occur[3].

Current Clinical Trials

Cevostamab is currently being studied in several clinical trials, including:

  • Phase 1 trials to determine the safe dose and initial effectiveness[1]
  • Phase 1b/2 trials exploring cevostamab alone or in combination with other drugs[4]
  • Studies looking at cevostamab in patients who have previously received BCMA-targeted therapies[2]
  • Trials investigating cevostamab as a maintenance therapy after stem cell transplantation[3]

Combination Therapies

Researchers are also studying cevostamab in combination with other drugs to potentially improve its effectiveness. Some combinations being explored include:

  • Cevostamab with pomalidomide and dexamethasone[4]
  • Cevostamab with daratumumab and dexamethasone[4]
  • Cevostamab with lenalidomide (as maintenance therapy after transplant)[3]
  • Cevostamab with iberdomide[3]
  • Cevostamab with elranatamab (another bispecific antibody)[5]

Potential Side Effects

As with all medications, cevostamab can cause side effects. One of the most important side effects to be aware of is cytokine release syndrome (CRS). This is an inflammatory response that can occur when the immune system is strongly activated. Symptoms of CRS can include fever, chills, low blood pressure, and difficulty breathing[1].

To help manage CRS, doctors may use a medication called tocilizumab. Some studies are also exploring whether giving tocilizumab before cevostamab can help prevent or reduce the severity of CRS[1].

Other potential side effects are being closely monitored in clinical trials. It’s important to note that the full range of side effects may not be known until more patients have been treated with cevostamab.

Future Prospects

Cevostamab shows promise as a new treatment option for multiple myeloma, particularly for patients who have not responded well to other therapies. Ongoing clinical trials are evaluating its effectiveness, safety, and optimal dosing strategies.

If the results from these trials continue to be positive, cevostamab could potentially become an important new tool in the treatment of multiple myeloma. However, it’s important to remember that as an investigational drug, cevostamab is still being studied and is not yet approved for general use outside of clinical trials[3].

Aspect Details
Drug Name Cevostamab (also known as BFCR4350A, RO7187797)
Condition Treated Relapsed/Refractory Multiple Myeloma (R/R MM)
Administration Method Intravenous (IV) infusion
Trial Phases Phase I, Phase Ib, Phase II
Key Objectives Safety, efficacy, pharmacokinetics, recommended Phase II dose
Combination Therapies Pomalidomide, daratumumab, lenalidomide, iberdomide
Primary Outcomes Adverse events, objective response rate, complete response rate
Secondary Outcomes Progression-free survival, overall survival, duration of response
Notable Side Effect Cytokine Release Syndrome (CRS)
CRS Management Tocilizumab administration

FAQ

  • What is cevostamab? Cevostamab is a new drug being tested in clinical trials for treating relapsed or refractory multiple myeloma, a type of blood cancer that has come back or stopped responding to previous treatments.
  • How is cevostamab given to patients? Cevostamab is usually given as an intravenous (IV) infusion, meaning it's delivered directly into the bloodstream through a vein. The dosing schedule can vary depending on the specific trial, but it's often given in cycles of 21 or 28 days.
  • What are the main goals of the cevostamab clinical trials? The main goals are to determine the safety of cevostamab, find the right dose to use, see how well it works against multiple myeloma, and understand how the body processes the drug (called pharmacokinetics).
  • Is cevostamab being studied alone or with other drugs? Cevostamab is being studied both alone and in combination with other drugs used to treat multiple myeloma, such as pomalidomide, daratumumab, lenalidomide, and iberdomide. Researchers are trying to find the most effective treatment combinations.
  • What are some potential side effects of cevostamab? While the full range of side effects is still being studied, one important side effect that researchers are monitoring is cytokine release syndrome (CRS). This is an immune system reaction that can cause fever and other symptoms. Doctors use a drug called tocilizumab to treat CRS if it occurs.

Ongoing Clinical Trials on Cevostamab

  • Study on the Safety and Efficacy of Cevostamab with Lenalidomide or Iberdomide for Patients with High-Risk or Relapsed Multiple Myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Poland Spain

  • Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that normally produces antibodies to fight infections.
  • Relapsed/Refractory Multiple Myeloma (R/R MM): Multiple myeloma that has either come back after treatment (relapsed) or has stopped responding to current treatments (refractory).
  • Cevostamab: An investigational drug being studied for the treatment of relapsed or refractory multiple myeloma.
  • Intravenous (IV) infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Cytokine Release Syndrome (CRS): A side effect that can occur with certain cancer treatments, causing symptoms like fever, nausea, and difficulty breathing due to an overactive immune response.
  • Tocilizumab: A medication used to treat cytokine release syndrome that may occur as a side effect of cevostamab treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Complete Response (CR): When all signs of cancer disappear after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without their cancer getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Minimal Residual Disease (MRD): A very small number of cancer cells that remain in the body during or after treatment.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Dose-Limiting Toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.
  • Recommended Phase II Dose (RP2D): The dose of a drug determined to be safe and effective for further testing in larger clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT03275103
  2. https://clinicaltrials.gov/study/NCT05535244
  3. https://clinicaltrials.gov/study/NCT05583617
  4. https://clinicaltrials.gov/study/NCT04910568
  5. https://clinicaltrials.gov/study/NCT05927571